Qualigen Therapeutics, Inc.
QLGN
$5.23
-$0.36-6.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -46.39% | 102.73% | |||
| Gross Profit | 46.39% | -102.73% | |||
| SG&A Expenses | -44.08% | 145.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -44.11% | 159.78% | |||
| Operating Income | 44.11% | -159.78% | |||
| Income Before Tax | 36.31% | -211.20% | |||
| Income Tax Expenses | -- | -100.00% | |||
| Earnings from Continuing Operations | 36.31% | -209.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.31% | -209.21% | |||
| EBIT | 44.11% | -159.78% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 44.84% | -66.76% | |||
| Normalized Basic EPS | 51.95% | -204.84% | |||
| EPS Diluted | 44.84% | -66.76% | |||
| Normalized Diluted EPS | 51.95% | -204.84% | |||
| Average Basic Shares Outstanding | 15.60% | 85.40% | |||
| Average Diluted Shares Outstanding | 15.60% | 85.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||